AN2 Therapeutics (ANTX) executive compensation, 2026 proxy

Eric Easom, President, Chief Executive Officer and Board Chair, was paid $1.4M in 2025, down 17% from $1.7M the year before.

Filed
April 22, 2026
Annual meeting
June 3, 2026
Pay year
2025
Named executives
3
CEO total pay
$1.4M-17% vs prior year
CEO pay in equity
32%$439,672 in awards
CEO 2025 Total Compensation
$1,382,985Decreased from prior year
CEO 2025 Salary
$603,750Unchanged from prior year
CEO Target Bonus Percentage
55%Expressed as percentage of base salary
Option Repricing Exercise Price
$3.91Effective March 19, 2026

How Easom was paid

$1.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary44%Stock awards12%Option awards20%Non-equity incentive24%All other compensation1%

Named executive officers

ExecutiveTotal
Eric EasomPresident, Chief Executive Officer and Board Chair$1,382,985
Josh EizenChief Legal Officer and Chief Operating Officer$807,080
Lucy DayChief Financial Officer$774,336

What changed and why

  • $1.4MCEO total compensation decreased to $1,382,985 in 2025 from $1,666,117 in 2024.
  • $332KEric Easom received a non-equity incentive plan compensation of $332,063 for 2025 performance.
  • $3.91The Board approved a stock option repricing reducing the exercise price of eligible options to $3.91 per share.
  • 100%Named executive officers were each awarded cash annual incentive bonuses equal to 100% of their target bonus amounts.
  • Lucy Day entered into an amended employment agreement reducing her role and base salary starting in 2026.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.